Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for purpose technology.

Indegene major competitors are Syngene Internation., Jubilant Pharmova, Granules India, Acutaas Chemicals, Blue Jet Healthcare, Natco Pharma, Alivus Life Sciences.
Market Cap of Indegene is ₹12,877 Crs.
While the median market cap of its peers are ₹14,833 Crs.

Indegene seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.